Axiom Biosciences is considering an initial public offering in Hong Kong, a rare move for an American biotechnology firm, and one that would help it tap China’s booming clinical development capabilities.
Geopolitics Bloomberg Jul 21, 2026
US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom
Axiom Biosciences is considering an initial public offering in Hong Kong, a rare move for an American biotechnology firm, and one that would help it tap China’s booming clinical development capabilities.
